Operator: Good morning, and welcome to the Cadence Pharmaceuticals Fourth Quarter and Full Year 2012 Financial Results Conference Call. On the call today are Ted Schroeder, President and CEO; Bill LaRue, Senior Vice President and Chief Financial Officer; and Scott Byrd; Senior Vice President and Chief Commercial Officer.
At this time, I would like to inform you that this conference is being recorded and that all participants are in a listen-only mode. At the request of the Company, we will open the conference up for questions and answers after the management presentation.
Our first speaker is Bill LaRue. Please go ahead, sir.
William R. LaRue - SVP, CFO: Thank you. Good morning, everyone. Before we begin, I would like to remind you that statements included in this conference call that are not a description of historical facts are forward-looking statements. Forward-looking statements include statements regarding Cadence's expectations regarding the time when it will be able to offer OFIRMEV in flexible plastic bags and the market for that product and the number of sites participating in the clinical pediatric trial for OFIRMEV. You are cautioned not to place undue reliance on these forward-looking statements, which speaks only as of the date hereof.
Our actual future results may differ materially from our current expectations due to the risks and uncertainties inherent in our business. These risks are detailed under risk factors in our most recent form 10-Q and upcoming form 10-K, as well as elsewhere in our periodic reports and other filings made with the Securities and Exchange Commission from time to time.
All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the Safe Harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and we undertake no obligation to revise or update the information discussed during this call to reflect events or circumstances after this call.
If anyone has not seen our press release issued today, you can access it on our website at www.cadencepharm.com. We also post and maintain the current version of our corporate presentation on the Investor’s portion of our website under Events and Presentations and then Corporate Overview.
Additionally, this conference call is being webcast through our website and will be archived there for future reference. We use the Investor’s portion of our website as one means of disclosing material non-public information. So we encourage you to monitor our website in addition to following our press releases, SEC filings, and public conference calls and webcasts. Ted?
Theodore R. Schroeder - President and CEO: Thanks, Bill. Good morning everyone, and thank you for joining us today. I will open by providing a brief overview of our accomplishments for the fourth quarter and the full year 2012. Next, Scott will provide an update on our commercial activities and the progress with OFIRMEV, and then Bill will discuss our financial results. Following our prepared remarks, we will open the call to your questions.